Parkinson's Disease And Related Disorders
, by Riederer, Peter; Reichmann, Heinz; Youdim, Moussa; Gerlach, Manfred
- ISBN: 9783211289280 | 3211289283
- Cover: Paperback
- Copyright: 6/15/2006
| An appreciation | p. 1 |
| A personal recollection | p. 5 |
| Pathology | |
| The discovery of dopamine deficiency in the parkinsonian brain | p. 9 |
| Synchronizing activity of basal ganglia and pathophysiology of Parkinson's disease | p. 17 |
| Basal ganglia discharge abnormalities in Parkinson's disease | p. 21 |
| Bad oscillations in Parkinson's disease | p. 27 |
| Cortical muscle coupling in Parkinson's disease (PD) bradykinesia | p. 31 |
| GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons | p. 41 |
| The engrailed transcription factors and the mesencephalic dopaminergic neurons | p. 47 |
| The role of Pitx3 in survival of midbrain dopaminergic neurons | p. 57 |
| Genetic analysis of dopaminergic system development in zebrafish | p. 61 |
| Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson's disease | p. 67 |
| The nigrostriatal DA pathway and Parkinson's disease | p. 71 |
| Relationship between axonal collateralization and neuronal degeneration in basal ganglia | p. 85 |
| Pathology associated with sporadic Parkinson's disease - where does it end? | p. 89 |
| Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease | p. 99 |
| A short overview on the role of a-synuclein and proteasome in experimental models of Parkinson's disease | p. 105 |
| The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help? | p. 111 |
| Iron and neuromelanin | |
| New face of neuromelanin | p. 119 |
| The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells | p. 125 |
| Potential sources of increased iron in the substantia nigra of parkinsonian patients | p. 133 |
| Iron and Friedreich ataxia | p. 143 |
| Genetics | |
| Nongenetic causes of Parkinson's disease | p. 147 |
| Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae? | p. 153 |
| CYP450, genetics and Parkinson's disease: gene × environment interactions hold the key | p. 159 |
| Unique cytochromes P450 in human brain: implication in disease pathogenesis | p. 167 |
| Cytochrome P450 and Parkinson's disease: protective role of neuronal CYP 2E1 from MPTP toxicity | p. 173 |
| Nicotine induces brain CYP enzymes: relevance to Parkinson's disease | p. 177 |
| Genetic causes of Parkinson's disease: extending the pathway | p. 181 |
| Progress in familial Parkinson's disease | p. 191 |
| Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins | p. 205 |
| Parkin and defective ubiquitination in Parkinson's disease | p. 209 |
| PINK-1 and DJ-1 - new genes for autosomal recessive Parkinson's disease | p. 215 |
| Clinical and pathologic features of families with LRRK2-associated Parkinson's disease | p. 221 |
| Molecular genetic findings in LRRK2 American, Canadian and German families | p. 231 |
| Imaging | |
| Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort | p. 235 |
| Neuroimaging in Parkinson's disease | p. 241 |
| Transcranial sonography in the early and differential diagnosis of Parkinson's disease | p. 249 |
| Models | |
| How to judge animal models of Parkinson's disease in terms of neuroprotection | p. 255 |
| Limitations of cellular models in Parkinson's disease research | p. 261 |
| The Rotenone model of Parkinsonism - the five years inspection | p. 269 |
| Controversies on new animal models of Parkinson's disease Pro and Con: the rotenone model of Parkinson's disease (PD) | p. 273 |
| Proposed animal model of severe Parkinson's disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum | p. 277 |
| ¿-Synuclein overexpression model | p. 281 |
| Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies | p. 285 |
| Clinical approaches | |
| What's new? Clinical progression and staging of Parkinson's disease | p. 305 |
| Parkinson's disease: premotor clinico-pathological correlations | p. 309 |
| Detection of preclinical Parkinson's disease along the olfactory trac(t) | p. 321 |
| The clinical approach to gait disturbances in Parkinson's disease; maintaining independent mobility | p. 327 |
| Getting around and communicating with the environment: visual cognition and language in Parkinson's disease | p. 333 |
| Cardiovascular aspects of Parkinson disease | p. 339 |
| Multiple system atrophy and autonomic failure | p. 343 |
| Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview | p. 349 |
| Sleep and wakefulness disturbances in Parkinson's disease | p. 357 |
| Neuroinflammation | |
| Parkinson's disease dementia: what's in a Lewy body? | p. 361 |
| Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10 | p. 367 |
| Role of cytokines in inflammatory process in Parkinson's disease | p. 373 |
| Neurosurgery | |
| Surgical therapy for Parkinson's disease | p. 383 |
| Deep brain stimulation for the treatment of Parkinson's disease | p. 393 |
| Deep brain stimulation in Parkinson's disease patients: biochemical evidence | p. 401 |
| Neurosurgery in Parkinson's disease: the doctor is happy, the patient less so? | p. 409 |
| L-Dopa | |
| Placebo effect and dopamine release | p. 415 |
| A new look at levodopa based on the ELLDOPA study | p. 419 |
| Thirty five years of experiencein the treatment of Parkinson's disease with levodopa and associations | p. 427 |
| Neuroprotection | |
| Concerning neuroprotective therapy for Parkinson's disease | p. 433 |
| Triggering endogenous neuroprotective mechanisms in Parkinson's disease: studies with a cellular model | p. 439 |
| Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression | p. 443 |
| M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease | p. 447 |
| Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety | p. 457 |
| Other treatment strategies | |
| Anti-apoptotic gene therapy in Parkinson's disease | p. 467 |
| The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors | p. 477 |
| Dystonia | |
| Pathophysiology of dystonia | p. 485 |
| Genetics of dystonia | p. 489 |
| Index | p. 497 |
| Listed in Current Contents/Life Sciences | |
| Table of Contents provided by Publisher. All Rights Reserved. |
What is included with this book?
The New copy of this book will include any supplemental materials advertised. Please check the title of the book to determine if it should include any access cards, study guides, lab manuals, CDs, etc.
The Used, Rental and eBook copies of this book are not guaranteed to include any supplemental materials. Typically, only the book itself is included. This is true even if the title states it includes any access cards, study guides, lab manuals, CDs, etc.
Please wait while the item is added to your bag...
×
Digital License
You are licensing a digital product for a set duration. Durations are set forth in the product description, with "Lifetime" typically meaning five (5) years of online access and permanent download to a supported device. All licenses are non-transferable.
More details can be found here.